New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia

Circulation Journal

Volumn 72, Issue 4, 2008, Pages 633-640

  Bir, Shyamal Chandra ^a   Fujita, Masatoshi ^a   Marui, Akira ^a   Hirose, Keiichi ^a   Arai, Yoshio ^a   Sakaguchi, Hisashi ^a   Huang, Yuhong ^a   Esaki, Jiro ^a   Ikeda, Tadashi ^a   Tabata, Yasuhiko ^b   Komeda, Masashi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Diabetic mouse; Growth factors; Hindlimb ischemia; Neovascularization; Serotonin blocker

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; SARPOGRELATE; SEROTONIN 2A RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HINDLIMB ISCHEMIA; LASER DOPPLER FLOWMETRY; LIMB ISCHEMIA; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STREPTOZOCIN DIABETES; SUSTAINED RELEASE FORMULATION;

ANIMALS; BASE SEQUENCE; COLLATERAL CIRCULATION; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DNA PRIMERS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; HINDLIMB; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN ANTAGONISTS; SUCCINATES;

EID: 43849107468     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.72.633     Document Type: Article

References (45)

1. Stamler J, Vaccsro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the multiple risk factor, interventional trial. Diabetes Care 1993; 16: 434-444.
2. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54: 718-721.
3. Abbott RD, Donahue RP, Kannel WB, Wilson PF. The impact of diabetes on survival following myocardial infarction in men versus women: The Framingham study. JAMA 1988; 260: 3456-3460.
4. European Working Group on Critical Leg Ischemia. Second European consensus document on chronic critical leg ischemia. Circulation 1991; 84(Suppl): IV-1-IV-26.
5. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF 165 in patient with ischemic limb. Lancet 1996; 348: 370-374.
6. Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized double blind control study of adenoviral delivery of VEGF 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938.
7. Carmeliet P. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis? Nat Med 2000; 6: 1102-1103.
8. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999; 5: 1359-1364.
9. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular specific growth factors and blood vessel formation. Nature 2000; 407: 242-248.
10. Feener EP, King GL. Vascular dysfunction in diabetes. Lancet 1997; 350(Suppl): I-9-I-13.
11. Abaci A, Oguzhan A, Kahraman S, Eryol NK, Unal S, Arinc H, et al. Effects of diabetes on formation of coronary collateral vessels. Circulation 1999; 99: 2239-2242.
12. Waltenberger J. Impaired collateral vessels development in diabetes: Potential cellular mechanism and therapeutic implications. Cardiovasc Res 2001; 49: 554-560.
13. Ferrara N, Gerber HP. Role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-156.
14. D'Amore PA, Smith SR. Growth factor effects on cell of the vascular wall; a survey. Growth Factors 1993; 8: 61-67.
15. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endcr Rev 1997; 18: 26-45.
16. Hosaka A, Koyama H, Kushibiki T, Tabata Y, Nishiyama N, Miyata T, et al. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collaterals. Circulation 2004; 110: 3322-3328.
17. Marui A, Kanematsu A, Yamahara K, Doi K, Kushibiki T, Yamamoto M, et al. Simultaneous application of basic FGF and HGF to enhance the blood vessel formation. J Vasc Surg 2005; 41: 82-90.
18. Iwakura A, Tabata Y, Koyama T, Doi K, Nishimura K, Kataoka K, et al. Gelatin sheet incorporating basic FGF to enhances sternal healing after harvesting bilateral internal thoracic arteries. J Thorac Cardiovasc Surg 2003; 126: 1113-1120.
19. Molyszko J, Urano T, Knofler R, Taminato A, Yoshimi T, Takada Y, et al. Daily variations of platelets aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75: 569-576.
20. 2 in reducing collateral blood flow by activated platelets. Am J Physiol Heart Circ Physiol 1993; 34: H158-H164.
21. Janiak P, Lainee P, Grataloup Y, Luyt C, Bidouard J, Michel J, et al. Serotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty zucker rat. Cardiovasc Res 2002; 56: 293-302.
22. Hirose K, Fujita M, Marui A, Arai Y, Sakaguchi H, Huang Y, et al. Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia. Circ J 2006; 70: 1190-1194.
23. 2 serotonergic receptor antagonist. Thromb Haemost 1991; 65: 415-420.
24. Rees DA, Alcolado JC. Animal models of diabetes mellitus. Diabetic Med 2004; 22: 359-370.
25. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998; 152: 1667-1679.
26. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-395.
27. van Royen N, Piek JJ, Buchmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardivasc Res 2001; 49: 543-553.
28. Simons M. Angiogenesis: Where do we stand now? Circulation 2005; 111: 1556-1566.
29. Weihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS, et al. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation 2004; 109: 2343-2348.
30. van Weel V, de Vries M, Voshol PJ, Verloop RE, Eilers PHC, van Hinsbergh VWM, et al. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1383-1390.
31. Fujita M, Tambara K. Recent insights into human coronary collateral development. Heart 2004; 90: 246-250.
32. Bushmann I, Schaper W. The pathophysiology of collateral circulation (arteriogenesis). J Pathol 2000; 190: 338-342.
33. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: Dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-191.
34. Tomanek RJ, Sanrda A, Zheng W, Brock T, Bjercke RJ, Holifield JS. Vascular endothelial growth factor and basic fibroblast growth factor differentially modulate early postnatal coronary angiogenesis. Circ Res 2001; 88: 1135-1141.
35. Klagsburn M. The fibroblast growth factor family: Structural and biological properties. Prog Growth Factor Res 1989; 1: 207-235.
36. Helisch A, Schaper W. Arteriogenesis: The development and growth of collateral arteries. Microcirculation 2003; 10: 83-97.
37. Kersten JR, Pagel PS, Chilian WM, Warltier DC. Multifactorial basis for coronary collateralization; a complex adaptive response to ischemia. Cardiovasc Res 1999; 43: 44-57.
38. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 2003; 38: 198-203.
39. Kinugawa T, Fujita M, Lee JD, Nakajima H, Hanada H, Miyamoto S. Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris. Am Heart J 2002; 144: E1.
40. Tanaka T, Fujita M, Nakae I, Tamaki S, Hasegawa K, Kihara Y, et al. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. J Am Coll Cardiol 1998; 32: 1982-1986.
41. Wentzel P, Ejdesjo A, Eriksson UJ. Maternal diabetes in vivo and high glucose in vitro diminish GAPDH activity in rat embryos. Diabetes 2003; 52: 1222-1228.
42. Biederman J, Yee J, Cortes P. Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis. Kidney International 2004; 66: 2308-2314.
43. Catalan V, Gomez-Ambrosi J, Rotellar F, Silva C, Rodriguez A, Salvador J, et al. Validation of endogenous control genes in human adipose tissue: Relevance to obesity and obesity-associated type 2 diabetes mellitus. Horm Metab Res 2007; 39: 495-500.
44. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004; 104: 2084-2086.
45. Lu H, Xu X, Zhang M, Cao R, Bråkenhielm E, Li C, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci USA 2007; 104: 12140-12145.